Journal of Applied Hematology

CASE REPORT
Year
: 2020  |  Volume : 11  |  Issue : 2  |  Page : 80--83

Hypereosinophilic syndrome posttreatment with triple-negative breast cancer


Khalid A AlSaleh 
 Department of Medicine, King Saud University Medical City, King Saud University, Riyadh, Kingdom of Saudi Arabia

Correspondence Address:
Dr. Khalid A AlSaleh
Department of Medicine, King Saud University, Riyadh
Kingdom of Saudi Arabia

Therapy-related secondary hematological changes play a crucial role in determining the life span of an otherwise recovered cancer patient after successful treatment. Hypereosinophilic syndrome (HES) is a potentially life-threatening condition when left unmanaged. The exact etiology of HES, however, remains elusive. We report a case of an adequately treated triple-negative breast cancer patient in remission, who presented with a confirmed diagnosis of HES 2 years after her therapy. On presentation, the blood picture showed leukocytosis of 42.7 × 109/L, where 20% were eosinophils. FIP1-like-1-platelet-derived growth factor receptor-alpha fusion was observed by fluorescence in situ hybridization. The patient was treated with imatinib, according to the World Health Organization guidelines, and full remission was achieved. This is the first case of HES postchemotherapy in a solid malignancy.


How to cite this article:
AlSaleh KA. Hypereosinophilic syndrome posttreatment with triple-negative breast cancer.J Appl Hematol 2020;11:80-83


How to cite this URL:
AlSaleh KA. Hypereosinophilic syndrome posttreatment with triple-negative breast cancer. J Appl Hematol [serial online] 2020 [cited 2020 Sep 30 ];11:80-83
Available from: http://www.jahjournal.org/article.asp?issn=1658-5127;year=2020;volume=11;issue=2;spage=80;epage=83;aulast=AlSaleh;type=0